期刊文献+

Total glucosides of paeony alleviates Sjogren syndrome through inhibiting inflammatory responses in mice

Total glucosides of paeony alleviates Sjogren syndrome through inhibiting inflammatory responses in mice
下载PDF
导出
摘要 OBJECTIVE To study the therapeutic effects of TGP on SS both in C57BL/6J mice immunized by immu⁃nological induction(SS mice)and NOD/ShiltJNju(NOD)mice.METHODS TGP(180,360,720 mg·kg^-1)was intragastri⁃cally administered for 6 or 16 weeks for SS mice and NOD mice,respectively.Weekly food and water intake,saliva flow,submandibular gland(SMG)and spleen index,and SMG pathology were measured.ELISA was used to evaluate serum interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)and autoantigens(SSA/Ro,SSB/La,andα-fodrin).Real-time PCR and Luminex liquid suspension chip assay were applied to analyze SMG inflammatory cytokines mRNA TNF-α,IL-17A,CXCL9,CXCL13,and B-cell activating factor(BAFF)and protein(IL-1β,IL-6,TNF-α,and IFN-γ)expres⁃sion.RESULTS Compared with SS mice,TGP(720 mg·kg^-1)treatment increased saliva flow,reduced organ indexes,and decreased serum IL-6 and IFN-γ concentration.TGP(360 mg·kg^-1)treatment decreased serum IFN-γ concentra⁃tion.TGP(180,360,720 mg·kg^-1)treatment improved SMG pathological damage.Compared with NOD mice,the saliva flowincreased from 9 to 15 weeks of administration.After 2 weeks of administration,TGP(720 mg·kg^-1)treatment decreased serum SSA/Ro,SSB/La and a-fodrin concentration,increased SMG index,inhibited SMG IFN-γ concentra⁃tion,and down-regulated SMG TNF-α,IL-17A,CXCL9,CXCL13 and BAFF mRNA expression.TGP(360 mg·kg^-1)treat⁃ment decreased serum SSB/La and a-fodrin,and SMG TNF-α and IFN-γ concentration,and down-regulated SMG TNF-α,IL-17A,CXCL9 and BAFF mRNA expression.TGP(180 mg·kg^-1)treatment decreased serum SSB/La,a-fodrin,and SMG IL-1β concentration,and down-regulated SMG TNF-α,IL-17A and BAFF mRNA expression.After 8 weeks of administration,TGP(180,360,720 mg·kg^-1)treatment increased SMG index,and decreased serum a-fodrin concentra⁃tion.TGP(720 mg·kg^-1)treatment down-regulated mRNA expression of SMG TNF-α,IL-17A,CXCL9,CXCL13,and BAFF.TGP(360 mg·kg^-1)treatment reduced mRNA expression of TNF-α,CXCL9,CXCL13 and BAFF,and concentra⁃tion of IL-6 and TNF-α.TGP(180 mg·kg^-1)treatment down-regulated mRNA expression of TNF-α,CXCL9,and CXCL13,and decreased IL-6 and TNF-αconcentration in SMG.After 16 weeks of administration,TGP(180,360,720 mg·kg^-1)treatment reduced serum SSA/Ro and a-fodrin concentration,increased SMG index,and decreased SMG CXCL13 and BAFF mRNA expression.TGP(360,720 mg·kg^-1)treatment decreased serum SSB/Laconcentration and SMG TNF-α,IL-17A and CXCL9 mRNA expression.Besides,TGP(180,360,720 mg·kg^-1)treatment alleviated the pathological damage of SMG after 2 and 16 weeks of administration.CONCLUSION TGP has a certain therapeutic effect onmice through inhibiting inflammatory responses. OBJECTIVE To study the therapeutic effects of TGP on SS both in C57 BL/6 J mice immunized by immunological induction(SS mice) and NOD/Shilt JNju(NOD) mice. METHODS TGP(180, 360, 720 mg·kg-1) was intragastrically administered for 6 or 16 weeks for SS mice and NOD mice, respectively. Weekly food and water intake, saliva flow,submandibular gland(SMG) and spleen index, and SMG pathology were measured. ELISA was used to evaluate serum interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), interferon-γ(IFN-γ) and autoantigens(SSA/Ro, SSB/La, and α-fodrin).Real-time PCR and Luminex liquid suspension chip assay were applied to analyze SMG inflammatory cytokines mRNA(TNF-α, IL-17 A, CXCL9, CXCL13, and B-cell activating factor(BAFF) and protein(IL-1β, IL-6, TNF-α, and IFN-γ) expression. RESULTS Compared with SS mice, TGP(720 mg·kg-1) treatment increased saliva flow, reduced organ indexes,and decreased serum IL-6 and IFN-γ concentration. TGP(360 mg·kg-1) treatment decreased serum IFN-γ concentration. TGP(180, 360, 720 mg·kg-1) treatment improved SMG pathological damage. Compared with NOD mice, the saliva flowincreased from 9 to 15 weeks of administration. After 2 weeks of administration, TGP(720 mg · kg-1) treatment decreased serum SSA/Ro, SSB/La and a-fodrin concentration, increased SMG index, inhibited SMG IFN-γ concentration, and down-regulated SMG TNF-α, IL-17 A, CXCL9, CXCL13 and BAFF mRNA expression. TGP(360 mg·kg-1) treatment decreased serum SSB/La and a-fodrin, and SMG TNF-α and IFN-γ concentration, and down-regulated SMG TNF-α,IL-17 A, CXCL9 and BAFF mRNA expression. TGP(180 mg·kg-1) treatment decreased serum SSB/La, a-fodrin, and SMG IL-1β concentration, and down-regulated SMG TNF-α, IL-17 A and BAFF mRNA expression. After 8 weeks of administration, TGP(180, 360, 720 mg·kg-1) treatment increased SMG index, and decreased serum a-fodrin concentration. TGP(720 mg·kg-1) treatment down-regulated mRNA expression of SMG TNF-α, IL-17 A, CXCL9, CXCL13, and BAFF. TGP(360 mg·kg-1) treatment reduced mRNA expression of TNF-α, CXCL9, CXCL13 and BAFF, and concentration of IL-6 and TNF-α. TGP(180 mg·kg-1) treatment down-regulated mR NA expression of TNF-α, CXCL9, and CXCL13,and decreased IL-6 and TNF-α concentration in SMG. After 16 weeks of administration, TGP(180, 360, 720 mg·kg-1)treatment reduced serum SSA/Ro and a-fodrin concentration, increased SMG index, and decreased SMG CXCL13 and BAFF mRNA expression. TGP(360, 720 mg·kg-1) treatment decreased serum SSB/Laconcentration and SMG TNF-α,IL-17 A and CXCL9 mR NA expression. Besides, TGP(180, 360, 720 mg·kg-1) treatment alleviated the pathological damage of SMG after 2 and 16 weeks of administration. CONCLUSION TGP has a certain therapeutic effect onmice through inhibiting inflammatory responses.
出处 《中国药理学与毒理学杂志》 CAS 北大核心 2019年第9期687-688,共2页 Chinese Journal of Pharmacology and Toxicology
关键词 total glucosides of paeony Sjogren syndrome inflammatory autoimmune disease inflammatory cytokine total glucosides of paeony Sjogren syndrome inflammatory autoimmune disease inflammatory cytokine
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部